Moleculin completes Part A enrollment in AML trial, eyes Q1 2027 data

September 29, 2026 8:45 AM

Moleculin Biotech, Inc. (Nasdaq: MBRX) announced it has completed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found